Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

GlobeNewswire April 4, 2022

ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

GlobeNewswire March 23, 2022

ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

GlobeNewswire March 7, 2022

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

GlobeNewswire February 24, 2022

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

GlobeNewswire February 11, 2022

ProQR to Present at Upcoming SVB Leerink Conference

GlobeNewswire February 7, 2022

ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

GlobeNewswire January 4, 2022

ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

GlobeNewswire December 30, 2021

ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

GlobeNewswire December 16, 2021

ProQR Announces Highlights from Analyst Event

GlobeNewswire November 18, 2021

ProQR to Webcast Virtual Analyst Event on November 18

GlobeNewswire November 11, 2021

ProQR Announces Upcoming Investor Conferences in November and December

GlobeNewswire November 8, 2021

ProQR Announces Third Quarter 2021 Operating and Financial Results

GlobeNewswire November 4, 2021

ProQR Appoints Theresa Heggie as Chief Commercial Officer

GlobeNewswire October 4, 2021

ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform

GlobeNewswire September 8, 2021

ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

GlobeNewswire September 8, 2021

ProQR Announces Virtual Presentation at EURETINA 2021

GlobeNewswire September 6, 2021

ProQR Announces Upcoming Investor Conferences

GlobeNewswire September 3, 2021

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference

GlobeNewswire August 11, 2021

ProQR Announces Second Quarter 2021 Operating and Financial Results

GlobeNewswire August 5, 2021